Time filter

Source Type

Nishi-Tokyo-shi, Japan

Kanzaki N.,Suntory Wellness Ltd. | Saito K.,Suntory Wellness Ltd. | Maeda A.,Suntory Wellness Ltd. | Kitagawa Y.,Suntory Wellness Ltd. | And 5 more authors.
Journal of the Science of Food and Agriculture | Year: 2012

Background: Oral glucosamine and chondroitin sulfate, alone and in combination, have been used worldwide for the treatment of osteoarthritis (OA), but their efficacy is controversial. This clinical study was aimed at investigating the potential of a dietary supplement containing glucosamine and chondroitin sulfate in combination with derivatives of quercetin, a naturally occurring flavonoid, (GCQ supplement) for knee OA care. Results: A randomized, double-blind, placebo-controlled study was conducted in 40 Japanese subjects with symptomatic knee OA. Subjects were randomly assigned to GCQ supplement (1200 mg glucosamine hydrochloride, 60 mg chondroitin sulfate and 45 mg quercetin glycosides per day) or placebo and the treatment and follow-up were continued for 16 weeks. The results of symptomatic efficacy assessment based on Japanese Orthopaedic Association criteria showed that scores for two of the four symptom/function subscales, as well as the aggregate scores, were significantly improved at week 16 or earlier in the GCQ group compared to the placebo group. Moreover, analyses of cartilage metabolism biomarkers showed a trend of improvement in type II collagen synthesis/degradation balance in the GCQ group during follow-up. Conclusion: GCQ supplement was thought to be more effective than placebo in decreasing the intensity of knee OA-associated clinical symptoms. © 2011 Society of Chemical Industry.

Yanagisawa Y.,Miyama Co. | Yamamoto T.,TTC Co.
Japanese Pharmacology and Therapeutics | Year: 2014

Objective: The aim of this study was to evaluate the intake of lactic bacteria (Lactobacillus brevis) on skin conditions in women who had mild dry skin conditions.Methods: Ten female subjects (average of 35.1 ± 8.6 years old) who had mild dry skin conditions received lactic bacteria (4 g; ∼4×10l0 cells) daily for 8 weeks, and skin conditions including skin hydration state, transepidermal water loss (TEWL), and skin viscoelasticity were evaluated.Results: The intake of lactic bacteria for 8 weeks significantly improved TEWL in the left forearm (from 7.35 ±1.61 to 6.83 ± 1.27 g/m2 h; P<0.05 by paired Student's f-test). Regarding the skin viscoelasticity, the parameters R5 (net elasticity) and R7 (the ratio of elastic recovery to the total deformation) significantly increased after 8 weeks of the intake of lactic bacteria (from 0.403±0.055 to 0.433±0.034Ur/Ue and from 0.268±0.045 to 0.289± 0.032Ur/Uf, respectively; P<0.05 by paired Student's r-test). A questionnaire revealed that subjective skin conditions significantly improved after the intake of lactic bacteria for 8 weeks.Conclusions: The intake of lactic bacteria is suggested to improve both objective and subjective quality of skin conditions.

Glass H.E.,University of the Sciences in Philadelphia | Glass J.M.,TTC Co.
Pharmaceutical Medicine | Year: 2011

Introduction: Latin America currently represents a relatively small but constant number of clinical sites for commercially funded studies. This article describes the profiles of sites and investigators involved in commercial clinical research and compares the results with published results of similar US investigators. In addition, the research examines investigators' motives for taking part in clinical research and the concerns these investigators have with the operational challenge of conducting these studies. Methods: The data were drawn from a survey of investigators involved in commercially funded clinical trials in Argentina, Brazil, Chile, Colombia, Ecuador, El Salvador, Guatemala, Honduras, Mexico, Peru and Venezuela. The questionnaire comprised a list of 12 reasons related to why an investigator might participate in a phase III clinical trial of a new compound being tested by a pharmaceutical company, and respondents were asked to rate the importance of each reason on a scale of 1-10, with 1 being not important at all and 10 being very important. Surveys were conducted in 2008-9 and data were compared with a published analysis of US clinical investigators. Factor analysis, ANOVA, chi-square, gamma statistics and approximate significance measures were used to analyse the survey responses. All analyses were conducted using SPSS version 17. Results: The clinical experience of Latin American investigators is generally somewhat less than that of US investigators. Among other things, Latin America conducts a vastly greater portion of its research in hospitals compared with the US; few investigators work in private practice, in contrast to the US pattern. In addition, a far larger percentage of clinical research is conducted at dedicated sites than is the case in the US. Latin American investigators, along with their US counterparts, stress the importance of taking part in medical innovation as the primary reason for their involvement in commercially funded clinical research. Latin American investigators especially value the opportunity to work with other physicians on the study. Financial considerations, while not unimportant in Latin America, are secondary to this desire to be a part of medical innovation. Latin American investigators do differ somewhat from the US respondents in the importance they place on certain operational aspects of a clinical study. For instance, Latin American investigators are distinctly more concerned that a major pharmaceutical company sponsors the study than is the case with US investigators. In general, with the one noteworthy exception of serious adverse event reporting, Latin American and US investigators seem to have fairly comparable areas of dissatisfaction in the conduct of clinical trials. Conclusions: Latin America represents a particularly attractive growth market for pharmaceutical products. With a population in the hundreds of millions the demand for prescription drugs will make the need to conduct clinical research there essential for global pharmaceutical companies. Understanding the motivation of Latin American investigators should be valuable in helping such companies develop their clinical trial strategies and tactics. © 2011 Adis Data Information BV. All rights reserved.

Yanagisawa Y.,Miyama Co. | Yamamoto T.,TTC Co. | Saito J.,Medical Station Clinic
Japanese Pharmacology and Therapeutics | Year: 2014

Objective: The aim of this study was to evaluate the intake of lactic bacteria (Lactobacillus brevis Miyavis LB) on immune function in healthy adult volunteers with slightly reduced salivary secretory immunoglobulin A (slgA). Methods: Eleven subjects (average of 41.0± 10.1 years old) who had slightly reduced salivary slgA received lactic bacteria (4 g; ∼4 X 1010 cells) daily for 8 weeks, and their immune functions, including salivary slgA level, natural killer (NK) cell activity, and lymphocyte blastoid transformation, were evaluated. Results: The intake of lactic bacteria for 8 weeks significantly increased NK cell activity (from 22.41 ±9.06% to 41.32± 14.21 %), concanavalin A-stimulated lymphocyte blastoid transformation (from 31463.8±4146.3 cpm to47744.0±4790.9cpm; P<0.05). The level of salivary slgA, however, was not significantly changed in this study. Conclusions: The intake of lactic bacteria is suggested to enhance immune function in adult humans.

Yanagisawa Y.,Miyama Co. | Yamamoto T.,TTC Co. | Kondo S.,Medical Corporation Kenshokai
Japanese Pharmacology and Therapeutics | Year: 2014

Objective: The aim of this study was to evaluate the intake of lactic bacteria (Lactobacillus brevis Miyavis LB) on factors related to lifestyle disease in adult volunteers with mild symptoms of lifestyle disease. Methods: Sixteen subjects (average of 47.7 ±7.9 years old) who had mild symptoms of lifestyle disease received lactic bacteria (4 g; ∼4 X 1010 cells) daily for 8 weeks, and their levels of lifestyle disease-related factors were evaluated. Results: The intake of lactic bacteria for 8 weeks significantly reduced systolic and diastolic blood pressure (from 132± 14 to 122± 17 mmHg and 85 ± 10 to 78 ± 10 mmHg, respectively P <0.05). In addition, serum total and LDL-cholesteroI reduced after 4th weeks after the intake (from237±29to220±29mg/dLand 150±32to 137±29mg/dL, respectively; P<0.05). Conclusions The intake of lactic bacteria is suggested to improve lifestyle disease symptoms in adult humans.

Discover hidden collaborations